Sonus files for EU approval of EchoGen

Article

Sonus Pharmaceuticals announced that the European Medicines EvaluationAgency (EMEA) has accepted the company's marketing authorizationapplication (MAA) for its EchoGen ultrasound contrast agent forcardiology and radiology indications. The application, if

Sonus Pharmaceuticals announced that the European Medicines EvaluationAgency (EMEA) has accepted the company's marketing authorizationapplication (MAA) for its EchoGen ultrasound contrast agent forcardiology and radiology indications. The application, if approved,would enable Sonus to market EchoGen in all 15 nations of theEuropean Union, according to the company.

The Bothell, WA-based company submitted its application underthe new centralized application procedure, whereby a generallybinding approval, valid for all EU nations, may be obtained bya single application. Sonus made the announcement at the Hambrecht& Quist Healthcare Conference in San Francisco this month.

The filing generated a $1 million milestone payment from marketingpartner Abbott Laboratories of Abbott Park, IL (SCAN 10/23/96).Sonus filed a new drug application for EchoGen with the Food andDrug Administration in September. Sonus is set to receive another$4.4 million in milestone payments this year from Abbott afterbeginning phase III trials for use of EchoGen in myocardial perfusionstudies.

In other Sonus news, the company announced that researchersfrom Albany (NY) Medical College showed the first publicly presentedimages of EchoGen-enhanced prostate studies at the RadiologicalSociety of North America meeting in December.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.